Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.ekir.2017.11.001 http://scihub22266oqcxt.onion/10.1016/j.ekir.2017.11.001 C5932134!5932134!29725641     free     free     free Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Kidney+Int+Rep 2018 ; 3 (2): 374-84 Nephropedia Template TP {{tp|p=29725641|t=2018. Proton Pump Inhibitor Usage and the Risk of Mortality in Hemodialysis Patients |pdf=|usr=}}{{29725641}} gab.com Text Proton Pump Inhibitor Usage and the Risk of Mortality in Hemodialysis Patients JO: Kidney Int Rep http://www.kidney.de/pget.php?&tw=1&pmid=29725641 #FOAvip Introduction: Long-term inappropriate proton pump inhibitors use (PPIs) is a matter of concern because of the risks associated with their long-term use in older patients with chronic conditions. The risk of PPI treatment in hemodialysis patients remains unexplored. Methods: We assessed the relationship between the use of PPIs and the risk of death in hemodialysis patients throughout a retrospective multicenter propensity score?matched study. Information about demographic, hemodialysis treatment, laboratory data, and concomitant medication was obtained from the EuCliD database (Fresenius Medical Care). We studied 1776 hemodialysis patients on PPI therapy compared to 466 patients not receiving PPIs. The resulting population comprising 2 groups of 410 matched patients was studied. Results: PPI use was associated with hypomagnesemia (Mg <1.8 mg/dl (0.75 mmol/l); odds ratio [OR] = 2.70, 95% confidence interval [CI] = 1.38?5.27, P < 0.01). The exposure to PPIs in the full patient cohort was identified as an independent predictor for all-cause mortality in both univariate (HR = 3.16, 95% CI = 1.69?5.90, P < 0.01) and multivariate (HR = 2.70, 95% CI = 1.38?5.27, P < 0.01) Cox regression models. Moreover PPI use was identified as a predictor of CV mortality (HR = 1.51, 95% CI = 1.05?2.20, P = 0.03) Of the 820 patients matched throughout the propensity score analysis, the hazard ratios for all-cause mortality (HR = 1.412, 95% CI = 1.04?1.93, P = 0.03) and CV mortality (HR = 1.67, 95% CI = 1.03?2.71, P = 0.04) were higher among patients on PPIs versus those not on PPIs. Conclusion: The study data suggest that the PPI treatment should be regularly monitored and prescribed only when indicated. Twit Text FOAVip Proton Pump Inhibitor Usage and the Risk of Mortality in Hemodialysis Patients ????Kidney Int Rep http://www.kidney.de/pget.php?&tw=1&pmid=29725641 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=29725641 #FOAvip English Wikipedia <ref>{{Cite pmid|29725641}}</ref> Proton Pump Inhibitor Usage and the Risk of Mortality in Hemodialysis Patients #MMPMID29725641 de Francisco AL; Varas J; Ramos R; Merello JI; Canaud B; Stuard S; Pascual J; Aljama P Kidney Int Rep 2018[Mar]; 3 (2): 374-84 PMID29725641show ga Introduction: Long-term inappropriate proton pump inhibitors use (PPIs) is a matter of concern because of the risks associated with their long-term use in older patients with chronic conditions. The risk of PPI treatment in hemodialysis patients remains unexplored. Methods: We assessed the relationship between the use of PPIs and the risk of death in hemodialysis patients throughout a retrospective multicenter propensity score?matched study. Information about demographic, hemodialysis treatment, laboratory data, and concomitant medication was obtained from the EuCliD database (Fresenius Medical Care). We studied 1776 hemodialysis patients on PPI therapy compared to 466 patients not receiving PPIs. The resulting population comprising 2 groups of 410 matched patients was studied. Results: PPI use was associated with hypomagnesemia (Mg <1.8 mg/dl (0.75 mmol/l); odds ratio [OR] = 2.70, 95% confidence interval [CI] = 1.38?5.27, P < 0.01). The exposure to PPIs in the full patient cohort was identified as an independent predictor for all-cause mortality in both univariate (HR = 3.16, 95% CI = 1.69?5.90, P < 0.01) and multivariate (HR = 2.70, 95% CI = 1.38?5.27, P < 0.01) Cox regression models. Moreover PPI use was identified as a predictor of CV mortality (HR = 1.51, 95% CI = 1.05?2.20, P = 0.03) Of the 820 patients matched throughout the propensity score analysis, the hazard ratios for all-cause mortality (HR = 1.412, 95% CI = 1.04?1.93, P = 0.03) and CV mortality (HR = 1.67, 95% CI = 1.03?2.71, P = 0.04) were higher among patients on PPIs versus those not on PPIs. Conclusion: The study data suggest that the PPI treatment should be regularly monitored and prescribed only when indicated. äProton Pump Inhibitor Usage and the Risk of Mortality in Hemodialysis (epmc).pdf DeepDyve Pubget Overpricing